No Data
No Data
No Data
No Data
No Data
Oncternal Announces First Patient Dosed In Fourth Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in
BenzingaApr 18 21:04
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
TipRanksApr 17 19:45
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 15 18:20
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $28.00.
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $28.00.
Zhitong FinanceApr 15 18:11
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $28
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics with a Buy and lowers the price target from $30 to $28.
Analyst UpgradesApr 15 18:10
Oncternal Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 197.87% HC Wainwright & Co. $30 → $28 Maintains Buy 01/29/2024 219.15% HC Wainwright & Co. $2 →
BenzingaApr 15 18:08
No Data
No Data